Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EPS (Weighted Average and Diluted) (2022 - 2025)

Vivos Therapeutics (VVOS) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.49 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 508.33% to -$0.49 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.77, a 65.7% increase, with the full-year FY2024 number at -$2.22, up 80.07% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.49 for Q3 2025 at Vivos Therapeutics, up from -$0.55 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.12 in Q3 2024 to a low of -$6.61 in Q4 2022.
  • A 4-year average of -$1.71 and a median of -$0.57 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 106.86% in 2024, then crashed 508.33% in 2025.
  • Vivos Therapeutics' EPS (Weighted Average and Diluted) stood at -$6.61 in 2022, then soared by 53.89% to -$3.05 in 2023, then surged by 90.82% to -$0.28 in 2024, then tumbled by 75.0% to -$0.49 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EPS (Weighted Average and Diluted) are -$0.49 (Q3 2025), -$0.55 (Q2 2025), and -$0.45 (Q1 2025).